Bispecific Antibodies
Beyond Ivonescimab: China’s Next $Billion PD-1/VEGF Bispecific Licensing Opportunities
With blockbuster deals by 3SBio, BioNTech, and Akeso, emerging Chinese PD-1/VEGF bispecifics like RC148, HB0025, JS207, and CS2009 are primed for billion-dollar licensing opportunities.